Prostate adenocarcinoma: Cellular and molecular abnormalities

Cancer Control

Volumn 8, Issue 6, 2001, Pages 551-561

  Mora, Linda B ^a   Buettner, Ralf ^a   Ahmad, Nazeel ^a   Bassel, Yaser ^a   Jove, Richard ^a   Seigne, John D ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; CELL ADHESION MOLECULE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL X; PROTEIN BIK; PROTEIN MCL 1; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; STAT PROTEIN; STAT3 PROTEIN; TELOMERASE; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; CANCER INVASION; CELL DIFFERENTIATION; CELL PROLIFERATION; HETEROZYGOSITY LOSS; MALIGNANT TRANSFORMATION; METASTASIS; NEUROENDOCRINE DISEASE; ONCOGENE; PATHOPHYSIOLOGY; PLOIDY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SCORING SYSTEM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UNITED STATES;

EID: 0035682515     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800612     Document Type: Review

References (65)

1. Precursors of prostatic cancer: Progression, regression and chemoprevention
2. Diagnosis of prostatic intraepithelial neoplasia: Prostate Working Group/consensus report
3. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statements 1999
4. Prostate tissue factors
5. Report on Prostate Cancer Tumor Marker Workshop 1999
6. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy
7. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia
8. Epidemiology and molecular biology of early prostatic neoplasia
9. Architectural patterns of high-grade prostatic intraepithelial neoplasia
10. Predictive factors in prostate cancer: Current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer
11. Hereditary prostate cancer: Epidemiologic and clinical features
12. Current status of linkage studies in hereditary prostate cancer
13. Gleason's classification of prostatic adenocarcinomas
14. Atypical hyperplasia, benign hyperplasia, and well-differentiated adenocarcinoma of the prostate
15. Histologic grading of prostate cancer: A perspective
16. Undergrading of prostate cancer biopsies: A paradox inherent in all biologic bivariate distributions
17. Heterogeneity of prostate cancer in radical prostatectomy specimens
18. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate
19. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: Perineural invasion lacks significance on multivariate analysis
20. Testis risk and prognostic factors. The pathologist's perspective
21. Comparison of microscopic vascularity in benign and malignant prostate tissue
22. Prostate cancer: Are new prognostic markers on the horizon?
23. Stage B Prostate cancer: Correlation of DNA ploidy analysis with histological and clinical parameters
24. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation
25. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer
26. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study
27. Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat
28. Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy
29. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer
30. State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey
31. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative
32. Recessive oncogenes: Current status
33. Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers
34. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: Comparison with prostatic adenocarcinoma and benign prostate
35. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
36. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy
37. p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: Analysis of laser capture microdissected specimens from non-transition and transition zones
38. Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder
39. Retinoblastoma gene mutations in primary human prostate cancer
40. KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese
41. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells
42. Recent advances in the histopathology and molecular biology of prostate cancer
43. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade
44. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
45. Epithelial-stromal interactions and tumor progression: Meeting summary and future directions
46. Molecular markers for predicting prostate cancer stage and survival
47. Transforming growth factor beta 1 as a biomarker for prostate cancer
48. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
49. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells
50. Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis
51. Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma
52. Prostate cancer microvessels: A novel method for three-dimensional reconstruction and analysis
53. The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: Correlation with neovascularization
54. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients
55. Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials
56. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy
57. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer
58. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia
59. Telomerase in urological malignancy
60. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy
61. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
62. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
63. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells
64. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway
65. Constitutive activation of Stat3 in human prostate tumors and cells lines: Inhibitors of Stat3 signaling block growth of prostate cancer cells